Toutes les études
Actif, mais pas en recrutementOBSERVATIONNEL

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

This study, called BONAPH1DE, is observing people who have been diagnosed with a rare inherited kidney condition called Primary Hyperoxaluria Type 1 (PH1). The main goal is to understand the natural journey of this condition as it progresses over many years. Researchers also want to see how a medicine called lumasiran, which is used to treat PH1, performs in everyday situations, specifically looking at how safe it is and how well it helps patients in the long term. This is an observational study, meaning participants will be monitored, but no new treatments are being tested as part of the study itself.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Sponsor
Alnylam Pharmaceuticals
Objectif d'inscription
207
Démarrer
13 déc. 2021
Achèvement estimé
02 Jan 2029

De quoi parle cette étude ?

Imagine a study that acts like a detailed diary of how a health condition affects people's lives over time. That's essentially what the BONAPH1DE study is doing for a rare kidney disease called Primary Hyperoxaluria Type 1 (PH1).

PH1 is a condition where the body produces too much of a chemical called oxalate, which can build up and damage the kidneys. This study aims to gather information on how PH1 typically progresses, from when it's first diagnosed through many years. Researchers want to understand the different ways the condition can affect people, what symptoms they experience, and how their health changes over time — all in real-world settings, not just in a controlled laboratory.

Another important part of this study is to see how a specific medicine, lumasiran, works for people with PH1 in their daily lives. Lumasiran is already approved for use, and this study will help doctors understand its long-term safety and how effective it is outside of very strict clinical trial environments. This kind of information is crucial for health professionals to give the best possible care to patients with PH1.

Points clés

  • This study is about a rare kidney condition called Primary Hyperoxaluria Type 1 (PH1).
  • It aims to understand how PH1 develops over many years.
  • Researchers will also observe how an existing medicine, lumasiran, works in daily life.
  • It's an 'observational' study, meaning no new treatments are being tested.
  • People of all ages with a PH1 diagnosis may be eligible to participate.

Qui peut être éligible ?

To be part of this study, you must have a confirmed diagnosis of Primary Hyperoxaluria Type 1 (PH1) from your doctor. This is the main requirement to join.

There are also some reasons why you might not be able to join. For example, if you are already taking part in another study that is testing a new medicine, you would not be eligible for this one. This helps make sure that the results of this study are clear and not influenced by other experimental treatments.

People of all ages, from children to adults, and of any gender can potentially participate, as long as they meet the diagnosis criteria for PH1 and are not in another trial for an experimental drug.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Do I have a confirmed diagnosis of Primary Hyperoxaluria Type 1 (PH1) from my doctor?
  2. Am I currently taking part in another clinical trial that is testing a new, experimental drug?
  3. Am I willing to allow my medical information related to my PH1 to be used for research?
  4. Am I comfortable with researchers gathering information during my routine doctor's visits?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

As an observational study, taking part in BONAPH1DE means researchers will collect information about your health and your PH1 condition over a period of time. This usually involves reviewing your existing medical records, and potentially collecting information during your routine doctor's appointments. You won't be given any new or experimental medications as part of this study; instead, researchers will simply observe how your condition progresses and how any treatments you are already receiving, like lumasiran, are affecting you in your normal life. The exact number of visits or assessments will depend on your individual healthcare plan and how often you see your doctor for your PH1. You will be asked if your medical information can be used for the study research.

Risques et avantages potentiels

The main benefit of taking part in this study is contributing to a better understanding of PH1, which could help improve care for future patients. Because this is an observational study, you will not be given any new treatments, so there are generally no additional risks beyond those associated with your usual medical care for PH1. You will continue to receive care from your own doctors as normal. You are free to withdraw from the study at any time without it affecting your medical care.

Locations (30)

  • Clinical Trial Site
    Code postal vérifié
    Phoenix, États-Unis
  • Clinical Trial Site
    Code postal vérifié
    Washington D.C., États-Unis
  • Clinical Trial Site
    Code postal vérifié
    Boston, États-Unis
  • Clinical Trial Site
    Code postal vérifié
    Rochester, États-Unis
  • Clinical Trial Site
    Code postal vérifié
    Cincinnati, United States
  • Clinical Trial Site
    Code postal vérifié
    Pittsburgh, United States
  • Clinical Trial Site
    Code postal vérifié
    Dallas, United States
  • Clinical Trial Site
    Code postal vérifié
    Houston, États-Unis
  • Clinical Trial Site
    Code postal vérifié
    Gand, Belgique
  • Clinical Trial Site
    Code postal vérifié
    Liège, Belgium
  • Clinical Trial Site
    Code postal vérifié
    Hamilton, Canada
  • Clinical Trial Site
    Code postal vérifié
    Toronto, Canada

Questions fréquentes

What is Primary Hyperoxaluria Type 1 (PH1)?

PH1 is a very rare inherited condition where your body produces too much oxalate, a substance that can build up and harm your kidneys.

Cette étude teste-t-elle un nouveau médicament ?

No, this study is not testing a new medicine. It's observing how an already approved medicine, lumasiran, works in real-life situations for people with PH1.

Que signifie 'étude observationnelle' ?

It means researchers will just gather information about your health and how your condition progresses over time, without giving you any experimental treatments or changing your usual medical care.

Combien de temps vais-je participer à l'étude ?

The study aims to look at how PH1 progresses over the long term, so participation could involve watching your health records over several years. Your doctors will be able to give you more specific details.

Will I have extra doctor's appointments?

Generally, no. Information for the study will be collected during your regular visits to the doctor for your PH1 care, not requiring additional appointments just for the study.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.